drugset / Trial / NCT06725992

Study to Evaluate Pharmacokinetic and Pharmacodynamic Drug Interactions and Safety of IY-NS250 and IY-NT-SR

NCT06725992

Phase 1 Completed 56 enrolled Il-Yang Pharm. Co., Ltd.
RandomizedCrossoverOpen-labelTreatment

Summary

This study comparative evaluation of safety and pharmacokinetic and pharmacodynamic properties in oral repeat administration of IY-NS250 and IY-NT-SR in healthy adult

Timeline

Start
2024-01-30
Primary completion
2024-04-13
Completion
2024-08-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Ilaprazole Small molecule 10 mg Oral
Subject Ilaprazole Small molecule 20 mg Oral
Background sodium bicarbonate Diagnostic / imaging agent 500 mg Oral

Indications

No indication recorded.